Nucleoside analogs in the treatment of chronic viral hepatitis. Efficiency and complications. (Q40649138)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7989703%20AND%20SRC:MED&resulttype=core&format=json

30 October 2019

review article

1 reference

title

Nucleoside analogs in the treatment of chronic viral hepatitis. Efficiency and complications (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7989703%20AND%20SRC:MED&resulttype=core&format=json

30 October 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7989703%20AND%20SRC:MED&resulttype=core&format=json

30 October 2019

author name string

C Trépo

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7989703%20AND%20SRC:MED&resulttype=core&format=json

30 October 2019

publication date

1 August 1994

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7989703%20AND%20SRC:MED&resulttype=core&format=json

30 October 2019

published in

Journal of Hepatology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7989703%20AND%20SRC:MED&resulttype=core&format=json

30 October 2019

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7989703%20AND%20SRC:MED&resulttype=core&format=json

30 October 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7989703%20AND%20SRC:MED&resulttype=core&format=json

30 October 2019

page(s)

142-144

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7989703%20AND%20SRC:MED&resulttype=core&format=json

A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group

30 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980386-1

7 January 2021

Antiviral agents: characteristic activity spectrum depending on the molecular target with which they interact.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980386-1

7 January 2021

Acyclovir enhances the antiviral effect of interferon in chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980386-1

7 January 2021

Therapeutic potential of acyclovir and of the interferons in HBV-related chronic active hepatitis due to HBV with or without HDV superinfection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980386-1

7 January 2021

Randomized controlled trial of adenine arabinoside 5'-monophosphate in chronic active hepatitis B: comparison of the efficacy in heterosexual and homosexual patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980386-1

7 January 2021

Therapeutic activity of vidarabine in symptomatic chronic active hepatitis related to HBV.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980386-1

7 January 2021

Foscarnet therapy in chronic hepatitis B virus E antigen carriers

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980386-1

7 January 2021

Preliminary evidence that azidothymidine does not affect hepatitis B virus replication in acquired immunodeficiency syndrome (AIDS) patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980386-1

7 January 2021

A pilot study of 2',3'-dideoxyinosine for the treatment of chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980386-1

7 January 2021

Inhibition of duck hepatitis B virus replication by 2',3'-dideoxycytidine. A potent inhibitor of reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980386-1

7 January 2021

Ribavirin treatment for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980386-1

7 January 2021

A pilot study of ribavirin therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980386-1

7 January 2021

Therapy of chronic hepatitis B with a 6-month course of ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980386-1

7 January 2021

The problem of antiviral therapy for chronic hepadnavirus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980386-1

7 January 2021

The carbocyclic analog of 2'-deoxyguanosine induces a prolonged inhibition of duck hepatitis B virus DNA synthesis in primary hepatocyte cultures and in the liver

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980386-1

7 January 2021

The reverse transcriptase of hepatitis B virus acts as a protein primer for viral DNA synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980386-1

7 January 2021

10.1016/S0168-8278(05)80386-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7989703%20AND%20SRC:MED&resulttype=core&format=json

30 October 2019

1 reference